Soleve, a new technology for the treatment of chronic back pain

Brian Fitzer, the National Sales Director at Soleve that has a revolutionary new technology for the treatment of chronic back pain joins eHealth Radio and Health Care & Pain Management Channels.
Listen to interview with host Eric Michaels and guest Brian Fitzer discuss the following:

• I would imagine Soleve is going to be a new company.  Could you give us a bit of a background on Soleve?
• What sort of patients would be ideal candidates for Soleve?
• Can you tell me about the procedure itself?
• Have there been any studies done on Soleve?
• I’m sure we have a lot of listeners currently experiencing back pain. What should that person’s next step be?

Duration: 8:02
Soleve™ is a physician ancillary service offering potential for increased revenue.
Soleve, Inc., headquartered in Akron, Ohio, is a dba and wholly owned subsidiary of Nervomatrix Ltd. Nervomatrix, Ltd., is a leading developer of noninvasive and drug-free solutions for treating lower back pain. FDA cleared and European CE mark-certified, Soleve™ Noninvasive Targeted Neurostimulation is a revolutionary non-surgical, drug-free option for the treatment of lower back pain that applies therapeutic electrical stimulation over multiple points across a broader area to help provide soothing relief to sufferers from lower back pain.
Cleared for commercialization in the U.S. in December 2010, Soleve™ Noninvasive Targeted Neurostimulaton is a unique physician ancillary service that addresses the chronic and ever-growing problem of lower back pain in the U.S.  As an ancillary physician service, Soleve™ offers physicans a possible in-practice option to second-tier opioids and more expensive third-tier surgeries and other invasive procedures.The Soleve pain relief modality has been in use as a physician ancillary service for general back pain at select U.S. clinical locations. Twenty-one systems have been sold to date.
Founded by Miguel Gorenberg, M.D., Nervomatrix, Ltd. (dba Soleve, Inc.) was initially supported by a collaborative relationship with the Chief Scientist of the State of Israel and Startvest (2006) Limited Partnership, the investing partners of Targetech Innovation Center Incubator. Dr. Miguel Gorenberg is the Director of the Nuclear Medicine Department at the Bnai Zion Medical Center, Haifa Israel, and a Clinical Assistant Professor at the Faculty of Medicine of the Technion - Israel Institute of Technology.

Website: soleve.com